Skip to main content
Industry News
Study looks at CV outcomes of ertugliflozin in T2D, ASCVD

Ertugliflozin was noninferior to placebo in reducing the risk for major adverse cardiovascular events -- a composite of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke -- among type 2 diabetes patients with atherosclerotic cardiovascular disease. The findings published in The New England Journal of Medicine were based on data from 8,238 type 2 diabetes patients with ASCVD.

Full Story: